|
Our second clinical investigation study Retrospective Observational Study on HR+ and HER2-Low (IHC 1+ or 2+ with ISH negative) and HER2-Ultralow (IHC 0 with membrane staining) Metastatic Breast Cancer [Protocol CSNDSI01] sponsored by DSI is well underway with 11 active sites and 191 patients enrolled!
- Cancer Center of Kansas – 33 patients
- Singing River – 30 patients
- HealthPartners – 30 patients
- Toledo – 26 patients
- Northwest Cancer Center – 26 patients
- Premier Hematology and Oncology – 17 patients
- Renown Health — 10 patients
- Zangmeister – 8 patients
- Profound Research LLC – 6 patients
- Cancer Care Associates of York - 5 patients
- Maryland Oncology — currently screening for eligible patients
As a quick reminder, this study is a retrospective study chart review and has been deemed to be IRB exempt by the Central IRB. Thanks to all who have already committed to this initiative, we look forward to filling out the remaining few open research site slots!
We are excited to share that we are working towards activating sites for our third Clinical Investigation study - DSI02: EGFRm NSCLC Dato- DXd sponsored by DSI. We look forward to engaging with initial sites and welcome additional participation!
If interested in participating in any of our clinical trials, please contact Rachel M. Condjella, Ph.D. — Senior Director of Clinical Investigations & Market Insights rcondjella@cornerstoneonc.com or Josh Ondatje – Director of Clinical Operations jondatje@cornerstoneonc.com and Lizette Clark — Director of Clinical Operations lclark@cornerstoneonc.com for more information.
|